- Clinical trial of dostarlimab cured 18 patients in the US of colorectal cancer
- One researcher said that it was the ‘first time this has happened’ in a cancer trial
- It is still too early to declare the drug a cancer cure because the trial was small
- Doctors are expanding trial for gastric, prostate and pancreatic cancer patients
A womb cancer drug has shocked experts with how effective it is against colorectal tumours, after it seemingly cured every patient in a trial.
The antibody therapy Dostarlimab, already approved for women in the UK, smashed expectations in a study at Memorial Sloan Kettering Cancer Center in New York.
All 18 colorectal cancer patients involved in the trial were still in remission one year after it finished, with no signs of tumour reformation.
Researchers said there were ‘a lot of happy tears’ among the participants. All 18 had been unsuccessfully treated with traditional therapies before signing up to the study.
While the trial was small, it sets up Dostarlimab as a potential cure for one of the most deadly common cancers.
Dr Luis Diaz, one of the lead researchers of the trial, said: ‘I believe this is the first time this has happened in the history of cancer. It’s really exciting. I think this is a great step forward for patients.’
- Ellen Brown: The Looming Quadrillion Dollar Derivatives Tsunami
- Janet Yellen Just Poured Lighter Fluid On Every Small Bank In America
- The Great Financial Collapse of 2023. Comparison of Bear Stearns’ collapse in March 2008 and Credit Suisse in March 2023.
- Ron DeSantis unveils legislation to BAN Central Bank Digital Currency in Florida, protecting citizens from a grave threat to civil liberties…
- Never in history have we had all three issues happening at once…
- Clearwater Mayor abruptly resigns… Council members left in stunned silence
- Sperm has been almost entirely replaced by spike proteins
- People are crashing…
- Armstrong: WOKE Culture is Destroying the Economy & our Nation
- 2023: A Year When Everything Is Suddenly Breaking Loose All At Once